HH2853
Drug timelines are a Plus or Pro feature.
2 regulatory and trial events tracked for HH2853, covering 2026-01-30 to 2026-01-30. Get the full timeline:
Most recent: Clinical Trial Update: Study to Evaluate Efficacy and Safety of HH2853 in Relapsed/Refractory Peripheral T-cell Lymphoma [Phase 1, Phase 2]